EXUBERA RECEIVES POSITIVE OPINION FROM EUROPE

Pfizer and Sanofi-Aventis have received a positive opinion from an advisory committee to the European Medicines Agency recommending approval of their inhalable insulin product, Exubera, for the treatment of diabetes. The Committee for Medicinal Products for Human Use, a division of the European Medicines Agency, issued the positive opinion, which is likely to be acted upon by the European Commission to make Exubera available for type 1 and 2 diabetes sufferers. The move follows similar recommendations made in the US.

Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_news.asp?guid=47FBD868-FCFE-46A3-AC9B-33C2FE7F48D8)